Literature DB >> 8787915

Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis.

T Ishii1, M Hosoya, S Mori, S Shigeta, H Suzuki.   

Abstract

The ribavirin concentration in hamster brains was measured by a high-performance liquid chromatography (HPLC) system and a bioassay system. When ribavirin was administered intracranially at a dosage of 10 mg/kg of body weight per day for 10 days, a dosage which results in 100% survival of hamsters infected with subacute sclerosing panencephalitis (SSPE) virus and which inhibits the replication of SSPE virus in hamster brains, the ribavirin concentration in the brains estimated by HPLC and bioassay was kept higher than 50 micrograms/g for 10 days. The effective concentration in vivo corresponds to the concentration at which ribavirin completely inhibits the replication of SSPE virus in vitro. The maximal tolerable ribavirin concentration for hamsters was calculated to be 150 micrograms/g. Although ribavirin shows toxicity to the animals at a relatively low concentration (250 to 400 micrograms/g), intrathecal or intraventricular administration of ribavirin should be explored for potential use in the treatment of patients with SSPE, while the ribavirin concentration in cerebrospinal fluid or brain tissue should be monitored.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787915      PMCID: PMC163092     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro.

Authors:  M Hosoya; S Shigeta; K Nakamura; E De Clercq
Journal:  Antiviral Res       Date:  1989-09       Impact factor: 5.970

2.  Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis--a multi-institutional collaborative study--The Inosiplex-SSPE Research Committee.

Authors:  Y Fukuyama; K Nihei; S Matsumoto; T Ebina; S Kamoshita; T Sato; M Arima; H Yabuuchi; S Ueda; S Ohtahara
Journal:  Brain Dev       Date:  1987       Impact factor: 1.961

3.  Oral ribavirin therapy for subacute sclerosing panencephalitis.

Authors:  J W Ogle; P Toltzis; W D Parker; N Alvarez; K McIntosh; M J Levin; B A Lauer
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

4.  Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases.

Authors:  J T Jabbour; J H Garcia; H Lemmi; J Ragland; D A Duenas; J L Sever
Journal:  JAMA       Date:  1969-03-24       Impact factor: 56.272

5.  Ribavirin enters cerebrospinal fluid.

Authors:  C Crumpacker; G Bubley; D Lucey; S Hussey; J Connor
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

6.  Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients.

Authors:  C E Jones; P R Dyken; P R Huttenlocher; J T Jabbour; K W Maxwell
Journal:  Lancet       Date:  1982-05-08       Impact factor: 79.321

7.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds.

Authors:  E De Clercq; M Cools; J Balzarini; R Snoeck; G Andrei; M Hosoya; S Shigeta; T Ueda; N Minakawa; A Matsuda
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

8.  Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters.

Authors:  Y Honda; M Hosoya; T Ishii; S Shigeta; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Induction of acute myoclonic encephalopathy in hamsters by subacute sclerosing panencephalitis virus.

Authors:  T Sugita; K Shiraki; S Ueda; N Iwa; H Shoji; M Ayata; S Kato
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

10.  Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon.

Authors:  H S Panitch; J Gomez-Plascencia; F H Norris; K Cantell; R A Smith
Journal:  Neurology       Date:  1986-04       Impact factor: 9.910

View more
  7 in total

1.  High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis.

Authors:  M Hosoya; S Shigeta; S Mori; A Tomoda; S Shiraishi; T Miike; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis.

Authors:  Mitsuaki Hosoya; Shuichi Mori; Akemi Tomoda; Kenji Mori; Yukio Sawaishi; Hiroshi Kimura; Shiro Shigeta; Hitoshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.

Authors:  Alexander N Freiberg; Melissa N Worthy; Benhur Lee; Michael R Holbrook
Journal:  J Gen Virol       Date:  2009-11-04       Impact factor: 3.891

Review 4.  Measles virus infection of the CNS: human disease, animal models, and approaches to therapy.

Authors:  Dajana Reuter; Jürgen Schneider-Schaulies
Journal:  Med Microbiol Immunol       Date:  2010-08       Impact factor: 4.148

Review 5.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

Review 6.  Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis.

Authors:  Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

Review 7.  Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds.

Authors:  Katharina S Schmitz; Mona V Lange; Lennert Gommers; Kim Handrejk; Danielle P Porter; Christopher A Alabi; Anne Moscona; Matteo Porotto; Rory D de Vries; Rik L de Swart
Journal:  Viruses       Date:  2022-05-29       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.